Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), Bharat Parenterals has informed that the National Stock Exchange of India vide its Circular No. NSE/CML/75748 dated August 14, 2026, has informed its Members that the equity shares of Bharat Parenterals (Symbol: BPLPHARMA) are permitted to trade and admitted to dealings on the Capital Market Segment of NSE with effect from August 17, 2026. Accordingly, the equity shares of the Company are now permitted to trade and admitted to dealings on NSE under the Permitted to Trade category, in addition to their existing listing on BSE. A copy of the aforementioned NSE Circular No. NSE/CML/75748 dated August 14, 2026 is enclosed for information and records.
The above information is a part of company's filings submitted to BSE.
